The Patent Finder

Taiho Pharmaceutical Co., Ltd.

145 patents currently held · Updated Nov 18, 2026
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 14 name spellings.

21
Ending by 2030
Jun 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Nov 26 to 30, 2026 · next Nov 26
  • 3 fees due Dec 18 to 25, 2026 · next Dec 18
  • 3 fees due Jan 4 to 18, 2027 · next Jan 4
  • 3 fees due Feb 6 to 20, 2027 · next Feb 6
  • 1 fee due Mar 24, 2027
    The maintenance fee for Pyrrolo[2,3-d]pyrimidine compound or salt thereof (US 10,421,760) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
  • 7 fees due Apr 6 to 29, 2027 · next Apr 6
  • 1 fee due May 17, 2027
    The maintenance fee for Nanoparticles containing pH-responsive peptide (US 9,186,389) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
  • 1 fee due Jun 5, 2027
    The maintenance fee for Pharmaceutical composition including sodium alkyl sulfate (US 11,833,151) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
  • 6 fees due Jul 2 to 30, 2027 · next Jul 2
  • 3 fees due Sep 1 to 5, 2027 · next Sep 1
  • 1 fee due Oct 23, 2027
    The maintenance fee for Combination Decitabine and Cedazuridine Solid Oral Dosage Forms (US 11,963,971) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
  • 1 fee due Nov 7, 2027
    The maintenance fee for Preparation and composition for treatment of malignant tumors (US 11,975,002) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,440,675Potentiator of radiation therapy
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,148,381Potentiator of radiation therapy
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,618,075Certain Compounds, Compositions and Methods
In force
 · High confidence
In forceHigh confidence
US 8,951,987Certain Compounds, Compositions and Methods
In force
 · High confidence
In forceHigh confidence
US 9,567,363Certain Compounds, Compositions and Methods
In force
 · Medium confidence
In forceMedium confidence
US 8,410,096Antitumor agent, kit and method of treating cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US RE46,284Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,530,490Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,304,427Acylthiourea compound or salt thereof, and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,062,035Piperazine compound capable of inhibiting prostaglandin D synthase
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 145 patents shown.
Pro members see all 145.
Pro members: see all 145 patents
Also on record, not counted in the 145: 4 patents in force now held by others · 70 lapsed for an unpaid fee · 149 ended at full term · 2 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

34 pending · 13 abandoned · 52 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited